Therapeutic Asset Ratings
220 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
IMMUNOGLOBULIN G1, ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYPE VEGFR-2 EXTRACELLULAR DOMAIN) (HUMAN MONOCLONAL IMC-1121B .GAMMA.-CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL IMC-1121B .KAPPA.-CHAIN, DIMER
gastric cancer
Taiho Pharmaceutical Co., Ltd.
P1
CC
(44)
e-602
gastric cancer
Palleon Pharmaceuticals, Inc.
P1/2
CC
(44)
H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-59*01 (99.0%) -(IGHD) -IGHJ3*02 (93.3%) T125>I (114), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-11*01 (96.8%) -IGKJ4*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa
gastric cancer
Kineta Inc.
P1/2
CC
(44)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
gastric cancer
Sensei Biotherapeutics, Inc.
P1/2
CC
(44)
Vactosertib
gastric cancer
David Wald
P1/2
CC
(44)
egf816
Gastric Cancer
Cancer Research UK
P2/3
CC
(43)
n-803
gastric cancer
ImmunityBio, Inc.
P2
CC
(42)
kd-496
gastric cancer
Peking University
P1
CC
(42)
[111in]-fpi-1967
gastric cancer
Fusion Pharmaceuticals Inc.
P1/2
CC
(41)
[18F]FPyQCP
gastric cancer
Blue Earth Diagnostics
P1/2
CC
(41)
[203pb]pb-psv359
gastric cancer
Perspective Therapeutics
P1/2
CC
(41)
[212pb]pb-psv359
gastric cancer
Perspective Therapeutics
P1/2
CC
(41)
[225Ac]-FPI-1966
gastric cancer
Fusion Pharmaceuticals Inc.
P1/2
CC
(41)
64cu-lnth-1363s
gastric cancer
Lantheus Medical Imaging
P1/2
CC
(41)
Amxt1501
gastric cancer
Aminex Therapeutics, Inc.
P1/2
CC
(41)
Anti-Kras G12V Mtcr Pbl
gastric cancer
National Cancer Institute (NCI)
P1/2
CC
(41)
azd4360
gastric cancer
AstraZeneca
P1/2
CC
(41)
azd5305
gastric cancer
AstraZeneca
P1/2
CC
(41)
azd5863
gastric cancer
AstraZeneca
P1/2
CC
(41)
azd7789
gastric cancer
AstraZeneca
P1/2
CC
(41)
Balstilimab
gastric cancer
Rottapharm Biotech
P1/2
CC
(41)
bhb810
gastric cancer
BigHat Biosciences, Inc.
P1/2
CC
(41)
bnt141
gastric cancer
BioNTech SE
P1/2
CC
(41)
Camizestrant
gastric cancer
AstraZeneca
P1/2
CC
(41)
Chm-2101 Car-T Cells
gastric cancer
Chimeric Therapeutics
P1/2
CC
(41)
Showing 76 to 100 of 220 assets
Previous
Page 4 of 9
Next
